

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 678111822US</u> Express Mail Label Number	<u>11/7/06</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
FELDMAN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/002809

FILED: 16 MARCH 2005

U.S. APPLICATION NO:

35 USC §371 DATE:

FOR: USE OF RENIN INHIBITORS IN THERAPY

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/002809, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7831



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Date:

11/7/06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33687-US-PCT
APPLICATION NO.APPLICANT
FELDMAN ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2003/0114389A1	6/19/03	Webb	514	19	
	AB	2003/229007	12/11/03	Levi et al.	514	2	
	AC	4,885,292	12/5/89	Ryono et al.	514	211	
	AD	5,376,638	12/27/94	Young et al.	514	12	
	AE	5,182,266	1/26/93	Kleinert	514	18	
	AF	5,202,322	4/13/93	Allen et al.	514	228.2	
	AG	5,821,232	10/13/98	Fossa	514	18	
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AI	0 518 676 A2	12/16/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	0 573 652 A1	9/17/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AK	EP 1 312 379 A1	5/21/03	EP			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AL	Allikmets, "Aliskiren Speedel " Current Opinion in Investigational Drugs, Vol. 3, No. 10, pp 1479-1482, (2002)
	AM	Azizi et al. "Pharmacologic Demonstration of the Synergistic Effects of combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption." J. Am. Soc. Nephrol 15: pp. 3126-3133 (2004).
	AN	Beers et al., The Merck Manual of diagnosis and Therapy, Seventeenth Edition XP002364176 (1999)
	AO	Boger et al., "Dose-dependent effects on blood pressure and the rennin-angiotensin system with a new orally active rennin inhibitor." Clinical Pharmacology and Therapeutics, vol. 53, no. 2, p 140 (1993)
	AP	Fossa et al., "Synergistic Effect on Reduction in Blood Pressure With coadministration of a Renin Inhibitor or an Angiotensin-Converting Enzyme Inhibitor With an Angiotensin II Receptor Antagonist" Drug Development Research 33: pp 422-428 (1994)
	AQ	Himmelmann et al., "Remikiren (Ro 42-5892) - An Orally Active Renin Inhibitor in Essential Hypertension" AJH, Vol. 9, No. 6, pp 517-522 (1996)
	AR	Maibaum et al. "Renin inhibitors as novel treatments for cardiovascular disease" Monthly Focus: Cardiovascular, Renal, Endocrine & Metabolic, Expert Opinion. Ther. Patents No. 13(5),pp 589-603 (2003)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33687-US-PCT
APPLICATION NO.APPLICANT
FELDMAN ET AL.
FILING DATE

Group

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA	WO 01/15673 A2	3/8/01	WO				
	BB	WO 01/15674 A	3/8/01	WO				
	BC	WO 03/035046A2	5/1/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BD	WO 03/097098A1	11/27/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BE	WO 03/099279A1	12/4/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BF	WO 03/099767A1	12/4/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BG	WO 92/10097	6/25/92	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BH	WO2004/002549A1	1/8/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BI	WO2004/002957A1	1/8/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BJ	WO2004/100871A2	11/25/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BK	WO 02/40007 A1	5/23/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BL	WO2005/023183A2	3/17/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BM	WO2005/054244A2	6/16/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO2005/070406	8/4/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO2005/077418A1	8/25/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>
	BR						<input type="checkbox"/>	<input type="checkbox"/>
	BS						<input type="checkbox"/>	<input type="checkbox"/>
	BT						<input type="checkbox"/>	<input type="checkbox"/>
	BU						<input type="checkbox"/>	<input type="checkbox"/>
	BV						<input type="checkbox"/>	<input type="checkbox"/>
	BW						<input type="checkbox"/>	<input type="checkbox"/>
	BX						<input type="checkbox"/>	<input type="checkbox"/>
	BY						<input type="checkbox"/>	<input type="checkbox"/>
	BZ						<input type="checkbox"/>	<input type="checkbox"/>
EXAMINER				DATE CONSIDERED				

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.